Dimerix acquires Phase 2-ready acute kidney injury drug candidate DMX-652 from Mission Therapeutics

PUBT · 1d ago
Dimerix acquires Phase 2-ready acute kidney injury drug candidate DMX-652 from Mission Therapeutics
  • Dimerix acquired DMX-652 from Mission Therapeutics for all indications, adding a Phase 2-ready acute kidney injury program.
  • Transaction includes composition-of-matter patent rights, an open US IND, FDA-cleared Phase 2 protocol, GMP supply, manufacturing know-how.
  • DMX-652 is an oral USP30 inhibitor; Phase 1 in 85 healthy volunteers reported no drug-related serious adverse events.
  • Deal broadens the renal pipeline beyond DMX-200 in Phase 3 FSGS, positioning Dimerix to run a Phase 2 AKI study.
  • Company cited an estimated US$ 3.5 billion AKI market opportunity in 2026, with no approved therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dimerix Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607170700PR_NEWS_USPR_____CN06876) on July 17, 2026, and is solely responsible for the information contained therein.